Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Evotec SE
  6. News
  7. Summary
    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Evotec and EQRx announce integrated drug discovery and development partnership

11/18/2021 | 01:32am EST

DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec and EQRx announce integrated drug discovery and development partnership

18.11.2021 / 07:29
The issuer is solely responsible for the content of this announcement.


 
  • EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM
  • PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCESSIBLE MEDICINES TO PATIENTS

Hamburg, Germany, and Cambridge, Mass., USA, 18 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a collaboration to design, discover and develop new therapeutic options for patients. The collaboration will help accelerate EQRx's pipeline expansion efforts by leveraging Evotec's unique data-driven, fully integrated R&D-platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

The collaboration will focus on multiple therapeutic targets in oncology and immunology. Under the terms of the agreement, EQRx and Evotec will collaborate on drug discovery, pre-clinical and clinical development. Evotec will lead drug discovery and pre-clinical development efforts, and EQRx will be responsible for clinical development, regulatory and commercialisation efforts. In addition to jointly funded research and development activities, Evotec will benefit from the potential commercial success of the assets developed within the partnership through a variable profit share mechanism.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "EQRx's ambitious and transformative mission to deliver important new therapies to patients at more affordable prices makes them an ideal partner for us. This exciting new partnership will expand the reach of our unique data-driven integrated R&D platform. We look forward to leveraging our combined knowledge, expertise and leading-edge technologies to advance new medicines against validated targets as rapidly as possible to make the biggest possible impact for patients."

"We continue to rapidly expand our early-stage development pipeline through access to innovative, next-generation drug discovery and engineering technologies," said Carlos Garcia-Echeverria, PhD, chief of Rx creation at EQRx. "This collaboration with Evotec will enable us to engineer and develop precision medicines in immunology and oncology with high quality and speed of execution. We look forward to a productive collaboration to bring innovative, affordable and accessible treatment options to people in need."


ABOUT EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. In August 2021, EQRx announced a proposed combination with CM Life Sciences III (Nasdaq: CMLTU) to accelerate its growth. The combination is expected to be completed in the fourth quarter of 2021. To learn more, visit
www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc. EQRx(TM) and Remaking Medicine(TM) are trademarks of EQRx, Inc.

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,000 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to
www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.



18.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1250055

 
End of News DGAP News Service

1250055  18.11.2021 

fncls.ssp?fn=show_t_gif&application_id=1250055&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about EVOTEC SE
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Evotec, Bristol Myers Squibb Expand Team-Up to Cover New Alzheimer's Treatment Approach
MT
01/11EVOTEC : expands neuroscience collaboration with Bristol Myers Squibb to include new targe..
PU
01/11Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targ..
EQ
01/04EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
01/04Evotec receives EUR 7.5 m grant for development of COVID-19 therapeutic
AQ
01/03Evotec Obtains 7.5 Million Euro Grant for Development of COVID-19 Therapeutic EVT075
MT
01/03Evotec Wins $9 Million German Government Funding for COVID-19 Therapy
MT
01/03EVOTEC : receives € 7.5 m grant for development of COVID-19 therapeutic
PU
01/03Evotec receives ? 7.5 m grant for development of COVID-19 therapeutic
EQ
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Financials
Sales 2021 581 M 663 M 663 M
Net income 2021 237 M 271 M 271 M
Net cash 2021 538 M 614 M 614 M
P/E ratio 2021 25,0x
Yield 2021 -
Capitalization 6 241 M 7 120 M 7 123 M
EV / Sales 2021 9,82x
EV / Sales 2022 8,80x
Nbr of Employees 4 081
Free-Float -
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 35,63 €
Average target price 44,56 €
Spread / Average Target 25,1%
EPS Revisions
Managers and Directors
Werner Lanthaler Chief Executive Officer
Enno Spillner Chief Financial Officer
Iris Löw-Friedrich Chairman-Supervisory Board
Cord E. Dohrmann Chief Scientific Officer
Craig L. Johnstone Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
EVOTEC SE-16.16%7 049
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684